Hormonal Agents Lead to Improved Outcomes in African Americans With Chemo-Naive mCRPC

Kristie L. Kahl

Megan McNamara, MD

Although African-American men are at a higher risk for metastatic castration-resistant prostate cancer (mCRPC) and have worse survival outcomes compared with Caucasian men, findings of a recent retrospective study suggested they may have a better response to several prostate cancer treatments.

The large study, presented during a presscast ahead of the 2019 Genitourinary Cancers Symposium, showed African-American mCRPC treated with novel hormonal therapies—namely abiraterone acetate (Zytiga) or enzalutamide (Xtandi)—lived 20% longer than their Caucasian counterparts.

Moreover, the median overall survival (OS) was 30 months in African-American patients, compared with 26 months in Caucasian patients—highlighting the need for prospective trials to validate…

Read More